

4/6
7/13/01
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,371)

In re Application of: **Thomason et al.**)
Serial No.: **09/391,861**) Before the Examiner: **C. Stroup**
Filed: **September 7, 1999**) Group Art Unit: **1633**
For: **Fibroblast Growth Factor-Like**)
Polypeptides)

Commissioner for Patents
Washington, D.C. 20231
U.S. Express Mail EL604652834US

Sir/Madam:

INFORMATION DISCLOSURE STATEMENT

This statement is filed under 37 C.F.R. § 1.97(c) in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form. Copies of the listed documents are enclosed.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

A check in the amount of \$180.00 for an information disclosure statement under 37 C.F.R. 1.97(c), pursuant to 37 C.F.R. 1.17(p), is attached. The Commissioner is authorized to charge any additional fees or credit any overpayment to Deposit Account No. 13-2490.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

Dated: July 5, 2001

By:


Donald Zuhn, Ph.D
Reg. No. P-48,710